Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious ...

The companies said Lundbeck will acquire all of Longboard's shares for $60 per share, which represents a premium of 54.2% to ...

H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the ...

After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...

The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals in a deal worth $2.6 billion ...

Danish pharmaceutical company H. Lundbeck A/S (HLUKY.PK, HLUKF.PK) and Longboard Pharmaceuticals, Inc. (LBPH), announced Monday an ...

H. Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing ...

Danish drugmaker H. Lundbeck has struck a deal to buy clinical-stage biopharmaceutical company Longboard Pharmaceuticals for about $2.6 billion. The companies on Monday said Lundbeck will pay $60 a ...

The Danish pharmaceutical company, with its US headquarters in Deerfield, is boosting its drug pipeline for serious brain ...

Danish pharmaceutical giant H. Lundbeck A/S has struck a $2.6 billion deal to acquire Longboard Pharmaceuticals, a U.S.-based ...

H Lundbeck agreed to acquire Longboard Pharmaceuticals in a US$2.6 billion deal that boosts its drug pipeline for serious ...